Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mianserin is a tetracyclic antidepressant used primarily for the treatment of depression and anxiety. It is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA). Its mechanism of action involves blocking alpha-adrenergic receptors and histamine H1 receptors while also interacting with certain serotonin receptors in the central nervous system. Mianserin has strong antihistaminic and hypnosedative effects but minimal anticholinergic activity. It weakly inhibits norepinephrine reuptake and stimulates norepinephrine release. The drug is often used when sleep disturbances are present in depression or for patients who may be more susceptible to side effects from other antidepressants[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mianserin.